Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

Green Tea Extract EGCG Blocks Amyloid Plaque Formation in Brain Cell Cultures

By BiotechDaily International staff writers
Posted on 20 Mar 2013
The green tea extract, (−)-epigallocatechin-3-gallate (EGCG) prevented formation of metal-associated amyloid-beta plaques in brain cell cultures and dissolved plaques that had already formed.

EGCG is the most abundant catechin in tea and is a potent antioxidant that may have therapeutic applications in the treatment of many disorders. It is found in green tea but not black tea.

Alzheimer's disease investigators at the University of Michigan (Ann Arbor, USA) investigated and compared the interaction and reactivity of EGCG with metal (copper and zinc) and metal-free A-beta species. Such a study was considered necessary, as chelation therapy, which involves the removal of heavy metals from the body, has been shown to be beneficial in lowering amyloid plaque levels. This is because A-beta aggregation is somewhat dependent on the metal ions copper and zinc, and A-beta deposition was impeded in transgenic mice treated with the antibiotic clioquinol, a known copper/zinc chelator.

In the current study, a team comprising chemists, biochemists, and biophysicists used advanced analytical techniques including ion mobility-mass spectrometry (IM-MS), two-dimensional NMR spectroscopy, and computational methods to study the interaction of EGCG and A-beta plaques in cultures of human brain cells.

They reported in the February 20, 2013, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS) that EGCG interacted with metal-A-beta species and formed small, unstructured A-beta aggregates more noticeably than in metal-free conditions. Incubation of cells with EGCG eliminated the toxicity presented by both metal-free A-beta and metal-A-beta plaques. EGCG bound to A-beta monomers and dimers, generating more compact peptide conformations than those from EGCG-untreated A-beta species and nontoxic ternary EGCG-metal-A-beta complexes were produced.

"A lot of people are very excited about this molecule," said senior author Dr. Mi Hee Lim, assistant professor of chemistry at the University of Michigan. "We used a multidisciplinary approach. This is the first example of structure-centric, multidisciplinary investigations by three principal investigators with three different areas of expertise. But we believe you have to have a lot of approaches working together, because the brain is very complex. We want to modify them [molecules like EGCG] for the brain, specifically to interfere with the plaques associated with Alzheimer's."

Related Links:

University of Michigan




comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Synthetic ion transporters can induce apoptosis by facilitating chloride anion transport into cells (Photo courtesy of the University of Texas, Austin).

Experimental Drug Kills Cancer Cells by Interfering with Their Ion Transport Mechanism

An experimental anticancer drug induces cells to enter a molecular pathway leading to apoptosis by skewing their ion transport systems to greatly favor the influx of chloride anions. To promote development... Read more

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.